Tayani Institute’s Post

@Kiawaheye covers all the topics you need, with all the excitement you want: Relevant surgical, medical, subspecialty, challenges, innovations and real-life case reviews on the hottest topics in Ophthalmology this year #Kiawaheye #ophthalmology #cme

🌟👁️ Discover the clinical advantages of high-dose EYLEA® HD (aflibercept) Injection HCP through the experiences of Drs. Kenneth Fan, Sherveen Salek, and David Brown. In a compelling series of interviews, these experts discuss the effectiveness of this treatment in managing severe retinal diseases, sharing their successes in transforming patient outcomes. Learn more about the potent impact of high-dose Eylea on ophthalmic care. #ASRS2024 #Ophthalmology #MedicalLeadership #VisionaryInOphthalmology #MedicalInnovation #RetinaSpecialists #EyeCareInnovation #VisionScience #MedTech #HealthcareTrends #ClinicalResearch ASRS – American Society of Retina Specialists Bayer Bayer | Ophthalmology

Our Ophthalmology capabilites and expertise are second to none. if you have a spare minute, watch the below. AC #syneos #opthalmology

Coming soon, next yeek we will talk about the universe of dry eye

📰In January, Ophthalmology and Therapy shared a retrospective study on the SING IMT™️. The study was conducted between February 2022 to June 2023 at the Policlinico Gemelli hospital in Rome which included participants with bilateral end-stage AMD. “Enhancing the Functional Performance of Patients with Late-Stage Age-Related Macular Degeneration Implanted with a Miniature Telescope using Rehabilitation Training” concludes that the SING IMT™️. shows promise in addressing visual acuity and functional outcomes in patients with late-stage AMD. However, researchers points out that a key part of the progress is the rehabilitation.  The results demonstrate significant improvements in reading skills and fixation stability, with most patients achieving benefits within 4–5 rehabilitation sessions. Note, the SING IMT™️ is not yet FDA approved. #MedicalDevice #Ophthalmology #VisionCare #MacularDegeneration   https://lnkd.in/eWmz7M8r

A big shoutout to the 460 dedicated peer reviewers who contributed their expertise to JAMA Ophthalmology in 2023! Your invaluable efforts ensure the rigor and quality of published research in the field. Dive into the article to learn more about the vital role these reviewers play in advancing ophthalmology. #PeerReview #OphthalmologyResearch #JAMANetwork

Many thanks to Mahmoud A. Khaimi, MD, Mark Gallardo, Norbert Koerber and Simon Ondrejka for highlighting the remarkably consistent outcomes achieved with iTrack™ Advance on an eye-by-eye basis... IOP reduction was observed in 98% eyes (58/59 eyes) over 12 months. As the consistency of these outcomes suggest, there is something to be said for treating all possible points of outflow resistance in the TM, SC and CC with canaloplasty 💫 📹 Watch the video abstract here: https://lnkd.in/gEfCC_wx 📖 Read the results here: https://lnkd.in/gAFyV5Hs . . . . . . . . . . . . . . . . . . . . The iTrack™ Advance has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma. The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open angle glaucoma. For full safety information, please visit: https://lnkd.in/gKWZaHGc #glaucoma #canaloplasty #viscodilation #iTrackAdvance

Are you wondering what benefits a reading center offers Sponsors pursuing neovascular Age-related Macular Degeneration (nAMD) studies with OCT endpoints? Curious to know what the common inclusion/exclusion eligibility criteria and endpoints are for these studies? MERIT's Medical Director of Ophthalmology, Dr. Shawn Wilker, provides insight & expertise in this on-demand webinar. Watch now: https://lnkd.in/ge7YV7jX #MERITCRO #MERITCROWebinar #YourClinicalEndpointExpert #clinicaltrials #clinicalresearch #ophthalmology #webinar #AgeRelatedMacularDegeneration

Hey Real World Ophthalmology! Considering the Partner Track? 🤝 “It’s the decisions that make a business grow, rather than the productivity of any one associate. As a partner, you can shape the practice how you want and share in that success.”- Dr. Neel Vaidya This is one of the many insightful topics covered in our monthly column, "Real World Ophthalmology Corner," available on Ophthalmology Management. In the May 2024 issue, RWO Team Member Shivani Majumdar and RWO Founder Dr. Lisa Nijm discuss the ins and outs of becoming a partner in private practice! 🌟 They interview Dr. Vaidya as he reveals perks and risks, strategies for success, and tips on making informed decisions. Want to hear more insight from fellow ophthalmologists currently in a partnership? Register for our signature RWO Virtual Meeting, "Top 10 Things I Wish I Knew Sooner" on September 28th! Read the full article at the link in our bio!  #RealWorldOphthalmology #ByPhysiciansForPhysicians #Ophthalmology #youngophthalmologists #PrivatePractice #CareerAdvice #MedicalCareer #PartnerTrack #YoungEyeSurgeons ”

Ophthopedia Update:Clinical outcome measures in vision and eye care: Traditionally, clinical outcome assessments have focused on the patient’s perspective through patient-reported outcome assessments; however, given the complexity, integration, and interactions of various participants within the clinical ophthalmology setting, we propose that additional diverse clinical perspectives should be explored in order to fully appreciate the value of care provided to patients. In this review we introduce a framework by which clinical outcome assessments (COAs) can be organized. #Ophthalmology #Eye #Ophthotwitter